[Tics and Tourette syndrome: diagnosis, course and treatment principles].
Identifieur interne : 001A17 ( Main/Exploration ); précédent : 001A16; suivant : 001A18[Tics and Tourette syndrome: diagnosis, course and treatment principles].
Auteurs : Jean-Luc Houeto [France] ; Pauline GiréSource :
- Presse medicale (Paris, France : 1983) [ 2213-0276 ] ; 2008.
Descripteurs français
- KwdFr :
- Agonistes alpha-adrénergiques (usage thérapeutique), Agonistes de la dopamine (usage thérapeutique), Antagonistes de la dopamine (usage thérapeutique), Antidyskinésiques (usage thérapeutique), Diagnostic différentiel (MeSH), Humains (MeSH), Modulateurs GABA (usage thérapeutique), Stimulation cérébrale profonde (MeSH), Syndrome de Tourette (complications), Syndrome de Tourette (diagnostic), Syndrome de Tourette (psychologie), Syndrome de Tourette (thérapie), Toxines botuliniques (usage thérapeutique), Troubles des tics (complications), Troubles des tics (diagnostic), Troubles des tics (psychologie), Troubles des tics (thérapie).
- MESH :
- diagnostic : Syndrome de Tourette, Troubles des tics.
- psychologie : Syndrome de Tourette, Troubles des tics.
- thérapie : Syndrome de Tourette, Troubles des tics.
- usage thérapeutique : Agonistes alpha-adrénergiques, Agonistes de la dopamine, Antagonistes de la dopamine, Antidyskinésiques, Modulateurs GABA, Syndrome de Tourette, Toxines botuliniques, Troubles des tics.
- Diagnostic différentiel, Humains, Stimulation cérébrale profonde.
English descriptors
- KwdEn :
- Adrenergic alpha-Agonists (therapeutic use), Anti-Dyskinesia Agents (therapeutic use), Botulinum Toxins (therapeutic use), Deep Brain Stimulation (MeSH), Diagnosis, Differential (MeSH), Dopamine Agonists (therapeutic use), Dopamine Antagonists (therapeutic use), GABA Modulators (therapeutic use), Humans (MeSH), Tic Disorders (complications), Tic Disorders (diagnosis), Tic Disorders (psychology), Tic Disorders (therapy), Tourette Syndrome (complications), Tourette Syndrome (diagnosis), Tourette Syndrome (psychology), Tourette Syndrome (therapy).
- MESH :
- chemical , therapeutic use : Adrenergic alpha-Agonists, Anti-Dyskinesia Agents, Botulinum Toxins, Dopamine Agonists, Dopamine Antagonists, GABA Modulators.
- complications : Tic Disorders, Tourette Syndrome.
- diagnosis : Tic Disorders, Tourette Syndrome.
- psychology : Tic Disorders, Tourette Syndrome.
- therapy : Tic Disorders, Tourette Syndrome.
- Deep Brain Stimulation, Diagnosis, Differential, Humans.
Abstract
The term "Tourette syndrome" designates the combination of tics with other symptoms. Gilles de la Tourette disease is one of its most frequent causes. It combines motor and vocal tics, with no identifiable cause, with self-mutilation and variable psychiatric comorbidity that may include obsessive-compulsive disorder (OCD) and other anxiety disorders, mood and personality disorders, and a syndrome of hyperactivity with attention disorders. The prevalence of Tourette syndrome is estimated at 0.1-1% of the general population. The condition begins during childhood and develops in a succession of periods of relative aggravation and remission of the tics. Most patients show improvement at the end of adolescence, but symptoms can persist into adulthood in approximately one third of patients. The cause of Gilles de la Tourette disease is unknown, but the role of genetic susceptibility has been suggested together with dysfunctions of the dopaminergic system and of neuron networks in associative and limbic areas of the basal ganglia and the prefrontal cortex. Treatment of Tourette syndrome and severe tics is often difficult and requires a multidisciplinary approach (neurologist, psychiatrist, psychologist and social workers). In mild forms, information and psychological management are usually recommended. Drug treatments--including neuroleptics--are essential in the moderate to severe forms of the disease. Psychiatric comorbidities, when present, often justify specific treatment. For the most severe forms of Gilles de la Tourette disease, preliminary results of treatment by deep brain stimulation of the associative and limb areas of the thalamus or pallidum have produced real hope of treatment, but nonetheless require confirmation.
DOI: 10.1016/j.lpm.2007.11.007
PubMed: 18191532
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Tics and Tourette syndrome: diagnosis, course and treatment principles].</title><author><name sortKey="Houeto, Jean Luc" sort="Houeto, Jean Luc" uniqKey="Houeto J" first="Jean-Luc" last="Houeto">Jean-Luc Houeto</name><affiliation wicri:level="3"><nlm:affiliation>Service de neurologie et CMRR, CHU de Poitiers, F-86021 Poitiers Cedex, France. j.l.houeto@chu-poitiers.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de neurologie et CMRR, CHU de Poitiers, F-86021 Poitiers Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation></author><author><name sortKey="Gire, Pauline" sort="Gire, Pauline" uniqKey="Gire P" first="Pauline" last="Giré">Pauline Giré</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18191532</idno><idno type="pmid">18191532</idno><idno type="doi">10.1016/j.lpm.2007.11.007</idno><idno type="wicri:Area/Main/Corpus">001A77</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A77</idno><idno type="wicri:Area/Main/Curation">001A77</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A77</idno><idno type="wicri:Area/Main/Exploration">001A77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Tics and Tourette syndrome: diagnosis, course and treatment principles].</title><author><name sortKey="Houeto, Jean Luc" sort="Houeto, Jean Luc" uniqKey="Houeto J" first="Jean-Luc" last="Houeto">Jean-Luc Houeto</name><affiliation wicri:level="3"><nlm:affiliation>Service de neurologie et CMRR, CHU de Poitiers, F-86021 Poitiers Cedex, France. j.l.houeto@chu-poitiers.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de neurologie et CMRR, CHU de Poitiers, F-86021 Poitiers Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation></author><author><name sortKey="Gire, Pauline" sort="Gire, Pauline" uniqKey="Gire P" first="Pauline" last="Giré">Pauline Giré</name></author></analytic><series><title level="j">Presse medicale (Paris, France : 1983)</title><idno type="eISSN">2213-0276</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic alpha-Agonists (therapeutic use)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (therapeutic use)</term><term>Deep Brain Stimulation (MeSH)</term><term>Diagnosis, Differential (MeSH)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine Antagonists (therapeutic use)</term><term>GABA Modulators (therapeutic use)</term><term>Humans (MeSH)</term><term>Tic Disorders (complications)</term><term>Tic Disorders (diagnosis)</term><term>Tic Disorders (psychology)</term><term>Tic Disorders (therapy)</term><term>Tourette Syndrome (complications)</term><term>Tourette Syndrome (diagnosis)</term><term>Tourette Syndrome (psychology)</term><term>Tourette Syndrome (therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agonistes alpha-adrénergiques (usage thérapeutique)</term><term>Agonistes de la dopamine (usage thérapeutique)</term><term>Antagonistes de la dopamine (usage thérapeutique)</term><term>Antidyskinésiques (usage thérapeutique)</term><term>Diagnostic différentiel (MeSH)</term><term>Humains (MeSH)</term><term>Modulateurs GABA (usage thérapeutique)</term><term>Stimulation cérébrale profonde (MeSH)</term><term>Syndrome de Tourette (complications)</term><term>Syndrome de Tourette (diagnostic)</term><term>Syndrome de Tourette (psychologie)</term><term>Syndrome de Tourette (thérapie)</term><term>Toxines botuliniques (usage thérapeutique)</term><term>Troubles des tics (complications)</term><term>Troubles des tics (diagnostic)</term><term>Troubles des tics (psychologie)</term><term>Troubles des tics (thérapie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Agonists</term><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term><term>Dopamine Agonists</term><term>Dopamine Antagonists</term><term>GABA Modulators</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Tic Disorders</term><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tic Disorders</term><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome de Tourette</term><term>Troubles des tics</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Syndrome de Tourette</term><term>Troubles des tics</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Tic Disorders</term><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Tic Disorders</term><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Syndrome de Tourette</term><term>Troubles des tics</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agonistes alpha-adrénergiques</term><term>Agonistes de la dopamine</term><term>Antagonistes de la dopamine</term><term>Antidyskinésiques</term><term>Modulateurs GABA</term><term>Syndrome de Tourette</term><term>Toxines botuliniques</term><term>Troubles des tics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Deep Brain Stimulation</term><term>Diagnosis, Differential</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Diagnostic différentiel</term><term>Humains</term><term>Stimulation cérébrale profonde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The term "Tourette syndrome" designates the combination of tics with other symptoms. Gilles de la Tourette disease is one of its most frequent causes. It combines motor and vocal tics, with no identifiable cause, with self-mutilation and variable psychiatric comorbidity that may include obsessive-compulsive disorder (OCD) and other anxiety disorders, mood and personality disorders, and a syndrome of hyperactivity with attention disorders. The prevalence of Tourette syndrome is estimated at 0.1-1% of the general population. The condition begins during childhood and develops in a succession of periods of relative aggravation and remission of the tics. Most patients show improvement at the end of adolescence, but symptoms can persist into adulthood in approximately one third of patients. The cause of Gilles de la Tourette disease is unknown, but the role of genetic susceptibility has been suggested together with dysfunctions of the dopaminergic system and of neuron networks in associative and limbic areas of the basal ganglia and the prefrontal cortex. Treatment of Tourette syndrome and severe tics is often difficult and requires a multidisciplinary approach (neurologist, psychiatrist, psychologist and social workers). In mild forms, information and psychological management are usually recommended. Drug treatments--including neuroleptics--are essential in the moderate to severe forms of the disease. Psychiatric comorbidities, when present, often justify specific treatment. For the most severe forms of Gilles de la Tourette disease, preliminary results of treatment by deep brain stimulation of the associative and limb areas of the thalamus or pallidum have produced real hope of treatment, but nonetheless require confirmation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18191532</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-0276</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2 Pt 2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Tics and Tourette syndrome: diagnosis, course and treatment principles].</ArticleTitle><Pagination><MedlinePgn>263-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lpm.2007.11.007</ELocationID><Abstract><AbstractText>The term "Tourette syndrome" designates the combination of tics with other symptoms. Gilles de la Tourette disease is one of its most frequent causes. It combines motor and vocal tics, with no identifiable cause, with self-mutilation and variable psychiatric comorbidity that may include obsessive-compulsive disorder (OCD) and other anxiety disorders, mood and personality disorders, and a syndrome of hyperactivity with attention disorders. The prevalence of Tourette syndrome is estimated at 0.1-1% of the general population. The condition begins during childhood and develops in a succession of periods of relative aggravation and remission of the tics. Most patients show improvement at the end of adolescence, but symptoms can persist into adulthood in approximately one third of patients. The cause of Gilles de la Tourette disease is unknown, but the role of genetic susceptibility has been suggested together with dysfunctions of the dopaminergic system and of neuron networks in associative and limbic areas of the basal ganglia and the prefrontal cortex. Treatment of Tourette syndrome and severe tics is often difficult and requires a multidisciplinary approach (neurologist, psychiatrist, psychologist and social workers). In mild forms, information and psychological management are usually recommended. Drug treatments--including neuroleptics--are essential in the moderate to severe forms of the disease. Psychiatric comorbidities, when present, often justify specific treatment. For the most severe forms of Gilles de la Tourette disease, preliminary results of treatment by deep brain stimulation of the associative and limb areas of the thalamus or pallidum have produced real hope of treatment, but nonetheless require confirmation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houeto</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Service de neurologie et CMRR, CHU de Poitiers, F-86021 Poitiers Cedex, France. j.l.houeto@chu-poitiers.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giré</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Tics et syndrome de Gilles de la Tourette: diagnostic, évolution et principes de traitement.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018726">Anti-Dyskinesia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018757">GABA Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000316" MajorTopicYN="N">Adrenergic alpha-Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018726" MajorTopicYN="N">Anti-Dyskinesia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001905" MajorTopicYN="N">Botulinum Toxins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018757" MajorTopicYN="N">GABA Modulators</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013981" MajorTopicYN="N">Tic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>42</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18191532</ArticleId><ArticleId IdType="pii">S0755-4982(07)00767-1</ArticleId><ArticleId IdType="doi">10.1016/j.lpm.2007.11.007</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Nouvelle-Aquitaine</li><li>Poitou-Charentes</li></region><settlement><li>Poitiers</li></settlement></list><tree><noCountry><name sortKey="Gire, Pauline" sort="Gire, Pauline" uniqKey="Gire P" first="Pauline" last="Giré">Pauline Giré</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Houeto, Jean Luc" sort="Houeto, Jean Luc" uniqKey="Houeto J" first="Jean-Luc" last="Houeto">Jean-Luc Houeto</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18191532
|texte= [Tics and Tourette syndrome: diagnosis, course and treatment principles].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18191532" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |